Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer

Area of Science:

• Immunology
• Oncology
• Cancer Immunotherapy

Background:

• FDA approval of anti-CTLA-4 antibody (Ipilimumab) for metastatic melanoma highlights immune checkpoint blockade efficacy.
• Ipilimumab is under clinical evaluation for advanced prostate cancer, with Phase III trials completed.
• CTLA-4 blockade enhances anti-tumor immunity by modulating T-cell responses.

Purpose of the Study:

• To investigate the optimal sequencing and dosing of anti-CTLA-4 antibody in combination with a GM-CSF-secreting vaccine (GVAX).
• To evaluate the efficacy of combining anti-CTLA-4/GVAX immunotherapy with low-dose chemotherapy.
• To explore pre-clinical benefits in a genetically engineered mouse model of autochronous prostate cancer (Pro-TRAMP).

Main Methods:

• Utilized the Pro-TRAMP mouse model for autochronous prostate cancer.
• Administered anti-CTLA-4 antibody and GVAX vaccine in varying sequences and doses.
• Incorporated low-dose cyclophosphamide into the combined treatment regimen for metastatic models.

Main Results:

• Combined treatment significantly increased effector CD8 T cells in the prostate.
• Enhanced tumor-antigen directed lytic function was observed.
• Maximal efficacy was achieved when CTLA-4 blockade followed vaccination; low-dose chemotherapy added pre-clinical benefit in metastatic models.

Conclusions:

• The optimal combination regimen involves sequential administration of anti-CTLA-4/GVAX immunotherapy.
• Incorporation of low-dose chemotherapy further enhances therapeutic effects.
• This combination strategy shows potential for translation into clinical trials for prostate cancer treatment.